이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Enzo Biochem 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Kara Cannon

최고 경영자

US$1.2m

총 보상

CEO 급여 비율	24.4%
CEO 임기	less than a year
CEO 소유권	0.3%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	1.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Kara Cannon 의 보수는 Enzo Biochem 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Apr 30 2024	n/a	n/a	-US$18m
Jan 31 2024	n/a	n/a	-US$23m
Oct 31 2023	n/a	n/a	-US$25m
Jul 31 2023	US$1m	US$299k	-US$25m
Apr 30 2023	n/a	n/a	-US$27m
Jan 31 2023	n/a	n/a	-US$24m
Oct 31 2022	n/a	n/a	-US$23m
Jul 31 2022	US$769k	US$270k	-US$20m
Apr 30 2022	n/a	n/a	-US$7m
Jan 31 2022	n/a	n/a	US$300k
Oct 31 2021	n/a	n/a	US$5m
Jul 31 2021	US$426k	US$265k	US$8m
Apr 30 2021	n/a	n/a	US$1m
Jan 31 2021	n/a	n/a	-US$11m
Oct 31 2020	n/a	n/a	-US$21m
Jul 31 2020	US$371k	US$220k	-US$29m
Apr 30 2020	n/a	n/a	-US$31m
Jan 31 2020	n/a	n/a	US$2m
Oct 31 2019	n/a	n/a	US$822k
Jul 31 2019	US$379k	US$220k	US$2m
Apr 30 2019	n/a	n/a	US$2m
Jan 31 2019	n/a	n/a	-US$23m
Oct 31 2018	n/a	n/a	-US$16m
Jul 31 2018	US$342k	US$198k	-US$10m
Apr 30 2018	n/a	n/a	-US$4m
Jan 31 2018	n/a	n/a	-US$2m
Oct 31 2017	n/a	n/a	-US$2m
Jul 31 2017	US$306k	US$193k	-US$3m

보상 대 시장: Kara 의 총 보상 ($USD 1.22M )은 German 시장( $USD 434.78K ).

보상과 수익: 회사가 수익성이 없는 동안 Kara 의 보상이 증가했습니다.

CEO

Kara Cannon (55 yo)

less than a year

테뉴어

US$1,221,793

보상

Ms. Kara Cannon serves as Chief Executive Officer at Enzo Biochem, Inc. from January 31, 2024 and serves as its Director from 2024 and served as its Interim CEO since September 5, 2023 until January 31, 20...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kara Cannon	CEO & Director	less than a year	US$1.22m	0.25% $ 133.4k
Steven Pully	Independent Chairperson of the Board	less than a year	데이터 없음	데이터 없음
Mary Tagliaferri	Independent Director	3.6yrs	US$210.00k	0.27% $ 140.7k
Bradley Radoff	Independent Director	2.4yrs	US$195.00k	8.19% $ 4.3m

1.5yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 이사회: EZB 의 이사회는 경험(평균 재직 기간 1.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Enzo Biochem 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

High number of new directors

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Recent updates

Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.23 loss in 2Q 2023)

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

Enzo Biochem, Inc. announced delayed annual 10-K filing

High number of new directors

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)

Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022

CEO & Director recently bought €190k worth of stock

Insider recently bought €4.8m worth of stock

High number of new and inexperienced directors

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023

Enzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022

Full year 2022 earnings released: US$0.38 loss per share (vs US$0.16 profit in FY 2021)

Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022

Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2

Enzo Biochem, Inc. to Launch Monkeypox Testing Services This Week

Enzo Biochem, Inc. Announces Executive Changes

Independent Director recently bought €258k worth of stock

Independent Director recently bought €262k worth of stock

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)

Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022

High number of new and inexperienced directors

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management Positions

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022

High number of new and inexperienced directors

Less than half of directors are independent

Insider recently bought €2.2m worth of stock

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insider recently bought €1.3m worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)

Insider recently bought €2.1m worth of stock

Enzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value Index

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)

Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a Director

Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)

Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEO

Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 Variants

Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021

New 90-day high: €2.76

Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession Committees

Enzo Biochem Receives FDA Emergency Use Authorization for Testing Pooled Samples on Three Platforms Including company’s GENFLEX™ Proprietary System for Detection of Coronavirus SARS-Cov-2

New 90-day high: €2.30

New 90-day high: €2.10

First quarter 2021 earnings released: EPS US$0.006

Enzo Biochem, Inc. to Report Q1, 2021 Results on Dec 09, 2020

Enzo Biochem, Inc. Announces Appointment of Ian B. Walters to Board of Directors

Enzo Biochem, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Enzo Biochem, Inc. Announces Resignation of Peter J. Clemens, IV from the Board of Directors as Class II Director

Enzo Biochem, Inc. Launches Portable Microplate Reader for Use with its Elisa and Assay Kits to Simplify Laboratory Workflow

Enzo Biochem Launches GoTestMeNow Online Platform for Consumers to Directly Order COVID-19 Laboratory Tests

New 90-day low: €1.66

Full year earnings released - €0.60 loss per share

Enzo Biochem, Inc. to Report Q4, 2020 Results on Oct 13, 2020

New 90-day low - €1.79

CEO 보상 분석

CEO

테뉴어